Literature DB >> 21173337

Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.

Amanda K Raymond, Puja K Puri, M Angelica Selim, Douglas S Tyler, Kelly Carter Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21173337     DOI： 10.1001/archdermatol.2010.367

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  2 in total

1.  A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

Authors:  G M Beasley; A P Coleman; A Raymond; G Sanders; M A Selim; B L Peterson; M S Brady; M A Davies; C Augustine; D S Tyler
Journal:  Ann Surg Oncol       Date:  2012-05-02       Impact factor: 5.344

2.  (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

Authors:  Tatiana C Schneider; Ellen Kapiteijn; Tom van Wezel; Jan W A Smit; Jacobus J M van der Hoeven; Hans Morreau
Journal:  BMC Cancer       Date:  2016-01-19       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.